

## Positive Quality Intervention: Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma

**Description:** This PQI will discuss the initiation and management of tazemetostat in the treatment of relapsed or refractory (R/R) follicular lymphoma (FL).

**Background:** Tazemetostat is a methyltransferase inhibitor indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for completed resection and adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test, such as via the cobas® EZH2 Mutation Test, and who have received at least 2 prior systemic therapies or who have no satisfactory alternative treatment options. For R/R FL, mutation status was determined using the cobas® EZH2 mutation test to detect: Y646X [S,H,C], Y646F, Y646N, A682G, and A692V. Patients in trials received 800 mg of tazemetostat orally twice daily until disease progression or unacceptable toxicity with tumor assessments every 8 weeks. For EZH2 mutant FL patients the ORR was 69% (n=42) with a CR of 12% and PR of 57%. EZH2 wild-type FL patients had an ORR of 34% (n=53) with a CR of 4% and PR of 30%.<sup>1,2</sup> Median duration of response was 10.9 months in the EZH2mut cohort and 13.0 months in the EZH2WT cohort; median progression-free survival was 13.8 months and 11.1 months. Main usage is currently within 3rd or greater line treatment with mutation typically seen in 2<sup>nd</sup>/3<sup>rd</sup> line R/R FL. Mutation is identified in 2<sup>nd</sup> or 3<sup>rd</sup> line if patient is positive. The treatment is fairly well tolerated; the most common adverse reactions (≥20%) in patients with R/R FL were fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain.<sup>1</sup> Only 8% of patients permanently discontinued therapy due to adverse events, and 9% of patients required dose reductions. A well tolerated medication such as tazemetostat can be considered without testing for mutation if other alternatives are deemed too intolerable.<sup>2,3</sup> Median time to response was 3.7 months in the MT EZH2 cohort and 3.9 months in the WT EZH2 cohort.

### PQI Process:

- Confirm acceptable diagnosis and associated indication
  - EZH2 testing is not required by most payers when tazemetostat is the most satisfactory option
    - [FDA-approved tests](#) for detection of EZH2 mutation in R/R FL
      - EZH2 mutational status can be determined through a single gene, tissue based test
      - [EZH2NOW Testing Program](#)
  - Patient who has received 2 systemic therapies
    - Consider testing patient for EZH2, if positive, would be considered eligible candidate
  - No satisfactory alternative treatment options
    - Patient that has received 2 previous lines of therapy, and is evaluated to not to be a good candidate for additional chemoimmunotherapy or other treatments, testing for an EZH2 mutation would not be necessary
  - Speak with provider as a potential alternative treatment to current pathway
- Recommended dosage of tazemetostat is 800 mg orally twice daily with or without food
- Dose modifications for adverse reactions
  - First Dose Reduction: 600 mg orally twice daily
  - Second Dose Reduction: 400 mg orally twice daily
  - Patients unable to tolerate 400 mg orally twice daily should permanently discontinue

**IMPORTANT NOTICE:** NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual's sole responsibility to seek guidance from a qualified healthcare professional. *Updated 9.2.23*

- Cytopenia dose modifications
  - Neutropenia (neutrophil count less than  $1 \times 10^9/L$ )
    - Withhold until neutrophil count is greater than or equal to  $1 \times 10^9/L$  or baseline
    - First occurrence, resume at same dose
    - Second and third occurrence resume at reduced dose
    - Permanently discontinue after third occurrence
  - Thrombocytopenia (platelet count less than  $50 \times 10^9/L$ )
    - Withhold until platelet count is greater than or equal to  $75 \times 10^9/L$  or baseline
    - First and second occurrence, resume at reduced dose
    - Permanently discontinue after third occurrence
  - Anemia (hemoglobin less than 8 g/DL)
    - Hold until improvement to Grade 1 or baseline, then resume at same or reduced dose
- Other adverse reactions (Grades 3 and 4)
  - Grade 3
    - Withhold until improvement to at least Grade 1 or baseline
    - For first and second occurrence, resume at reduced dose
    - Permanently discontinue after third occurrence
  - Grade 4
    - Withhold until improvement to at least Grade 1 or baseline
    - For first occurrence, resume at reduced dose
    - Permanently discontinue after second occurrence

#### Patient-Centered Activities<sup>1</sup>:

- Provide [Oral Chemotherapy Education \(OCE\)](#) sheet and counsel patient on potential drug interactions
- Counsel patient on common side effects including pain, fatigue, nausea, decreased appetite, vomiting, and constipation
- Inform patient that they should avoid grapefruit and grapefruit juice
- If a dose is missed, skip and take at the next scheduled time
- Patient Assistance: [NCODA Financial Assistance Tool](#)

#### References:

1. TAZVERIK® (tazemetostat) [prescribing information].
2. Morschhauser F, Tilly H, Chaidos A, et al. Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma. *Blood*. 2019;134(suppl 1):123. doi:10.1182/blood-2019-128096.
3. Burke, JM, Bucholtz, E, et al. New Developments in Follicular Lymphoma: Treatment Guidance and Clinical Resources. *Clinical Care Options Oncology*. 2020.